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Abstract
Background: With less than a 5% survival rate pancreatic adenocarcinoma (PDAC) is almost uniformly lethal. In order to
make a significant impact on survival of patients with this malignancy, it is necessary to diagnose the disease early, when
curative surgery is still possible. Detailed knowledge of the natural history of the disease and molecular events leading to its
progression is therefore critical.
Methods and Findings: We have analysed the precursor lesions, PanINs, from prophylactic pancreatectomy specimens of
patients from four different kindreds with high risk of familial pancreatic cancer who were treated for histologically proven
PanIN-2/3. Thus, the material was procured before pancreatic cancer has developed, rather than from PanINs in a tissue field
that already contains cancer. Genome-wide transcriptional profiling using such unique specimens was performed. Bulk
frozen sections displaying the most extensive but not microdissected PanIN-2/3 lesions were used in order to obtain the
holistic view of both the precursor lesions and their microenvironment. A panel of 76 commonly dysregulated genes that
underlie neoplastic progression from normal pancreas to PanINs and PDAC were identified. In addition to shared genes
some differences between the PanINs of individual families as well as between the PanINs and PDACs were also seen. This
was particularly pronounced in the stromal and immune responses.
Conclusions: Our comprehensive analysis of precursor lesions without the invasive component provides the definitive
molecular proof that PanIN lesions beget cancer from a molecular standpoint. We demonstrate the need for accumulation
of transcriptomic changes during the progression of PanIN to PDAC, both in the epithelium and in the surrounding stroma.
An identified 76-gene signature of PDAC progression presents a rich candidate pool for the development of early diagnostic
and/or surveillance markers as well as potential novel preventive/therapeutic targets for both familial and sporadic
pancreatic adenocarcinoma.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in
the United States and its frequency has been rising in recent years
[1]. Due to lack of clinically overt symptoms the majority of
patients present with a disseminated disease and are largely
incurable. The abysmally low survival rate could be greatly
improved by effective methods of early detection, while cancer is
still surgically curable, with a ‘window of opportunity’ for the
timely diagnosis (e.g. the pre-metastatic stage of cancer) being,
according to a recent report, more than a decade [2]. Such
diagnostic methods will almost certainly include molecular
analysis, and yet very few large-scale studies to investigate the
process of early development of pancreatic cancer have been
undertaken.
A widely accepted paradigm is that PDAC develops through
series of precursor lesions called PanINs (pancreatic intraepithelial
neoplasia). Based on the degree of cellular and nuclear atypia,
these lesions progress from PanIN-1, characterized by hyperplastic
columnar ductal epithelia with no nuclear atypia, through PanIN-
2, that displays low-grade dysplasia, to PanIN-3 (carcinoma in situ),
which shows high-grade dysplasia [3]. The linearity of this
progression is still unclear, although, based on several reports
which show frequent PanIN-1 lesions in otherwise healthy people
and taking into account the low prevalence of PDAC associated
with PanIN-1, these early stage lesions are probably indolent in
nature. In contrast, based on available molecular data, PanIN-2
and -3 lesions are highly likely to be the true PDAC precursors
[4,5].
A major obstacle for the detailed study of PDAC evolution is
obtaining clinical material from PanIN lesions, which is a
particularly daunting task since the patients are largely asymp-
tomatic and these ductal changes are typically focal. In fact,
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PanIN-2 and -3 lesions are usually random findings in pathological
sections of specimens with frank malignancy and are often not
recorded in routine histopathological evaluation.
In this study, in order to reconstruct the natural history of the
disease, we analysed fresh frozen pancreatic tissue that had
dysplastic PanIN-2 and focal PanIN-3 lesions as the most
advanced histological abnormalities in the pancreas, without an
accompanying cancer. This is critical as use of dysplastic lesions
from adenocarcinoma cases could risk the inclusion of field defects
and duct cancerisation that are absent in specimens which are still
cancer-free. Such material would not be randomly available; it was
obtained from high-risk patients who inherit pancreatic cancer
and are participating in a cancer surveillance program developed
at the University of Washington [6,7].
The study of families in which cancer is inherited in an
autosomal dominant fashion has provided considerable insight
into the molecular basis of the disease; inherited pancreatic
cancers represent up to 10% of all pancreatic cancers [8,9]. We
have analysed four familial pancreatic cancer (FPC) cohorts,
Family X [10] and three additional pedigrees (here termed non-X
families) and contrasted them with normal pancreas and sporadic
pancreatic cancer. Family X has a rare, highly penetrant,
autosomal dominant form of FPC that is characterised by a
germline mutation in the palladin gene, an embryonic protein that
regulates cell motility and invasion [11]. The non-X FPC families
were a heterogeneous population with unknown germline
mutational status; no mutations were detected in CDKN2A (data
not shown) and further testing for BRCA2, PALB2 and ATM was
not performed due to the general low prevalence of these gene
mutations in FPC and the insufficient amount of material.
The transcriptomic, and proteomic [12] profiling of advanced
human PanINs from such families is critical for revealing the
molecular changes underlying the progression towards PDAC and
might provide a framework for devising novel surveillance,
preventive, and treatment modalities.
Results
The pedigrees of four different FPC families with at least two
affected members are shown in Figure 1. Three smaller kindreds
(A, B and C) have in addition to PDAC also other solid
malignancies, while Family X (X), which is characterised by early
onset disease and often preceded by endocrine (Diabetes mellitus)
and exocrine insufficiency [10,13] is affected only by PDAC. The
patients from which samples were obtained are circled in
Figure 1; patients’ clinical information is summarized in Table 1.
Figure 2 shows that familial PanINs resembled sporadic
PanINs; however, while areas of adjacent, normal-appearing
pancreas (marked by *) were seen in the non-X specimens,
pronounced widespread acinar atrophy, fibrosis and multicystic
appearance was only seen in Family X.
Whole transcriptome analysis
Gene expression of 13 PanIN samples was compared to
profiling data of whole biopsies from normal donor pancreas
(N1 to 4, two replicated samples) and sporadic PDAC (PDAC1 to
6). Unsupervised hierarchical clustering showed a clear separation
of samples into four distinct clusters; non-X and Family X PanINs
fell into two discrete groups, the former being closer to normal
samples, while PDACs formed a single distant cluster (Figure S1).
The most commonly up-regulated genes in all PanINs
compared to the normal samples were AGR2, S100P, TFF1,
LDLR and EMP1, and down-regulated were OLFM4, REG3G,
REGL1, and ASNS. When PanIN samples were compared to
PDACs, the most commonly up-regulated genes in the cancers
were POSTN, COL1A2, SULF1, FN1, IGHM, VCAN and
XIST, and these down-regulated were PGC and PPY.
The Venn diagram in Figure 3A shows the total number of
gene changes across the three comparisons (non-X, X and PDAC)
versus normal pancreas and demonstrates the overall lower
number of differentially expressed genes between non-X vs
normal pancreas in comparison to Family X vs normal tissue.
While this is partially due to the presence of remaining normal-
appearing tissues that was more abundant in non-X samples, as
the proportion of shared deregulated genes in Family X and
sporadic PDACs (900/2292, 39%) was higher than in non-X
families (125/443, 28%), this could potentially also underlie the
higher aggressiveness of the Family-X PanINs, manifested in their
earlier clinical presentation. This was also seen using IPA’s
Multiple comparison analysis: the most significant ‘Molecular and
cellular functions’ which comprise the majority of cancer
hallmarks [14] (Figure 4A) are all being increasingly affected
during neoplastic progression from the PanIN-2/3 to the PDAC
and are consistently higher in Family X than in non-X families. Of
note, the graphs show the significance of the modules rather than
the number of affected genes or direction of their changes.
In addition to shared features, differences between the non-X
and X PanINs and PDAC specimens were also seen, particularly
in the ‘seventh hallmark of cancer’, immune functions [15,16].
The most affected canonical pathways are shown in Figure 4B.
The highest ranked ‘Antigen Presentation’ was predominantly
affected in non-X families, with the decrease in the key
components of antigen-presenting machinery (CD74, HLA-A/B,
HLA-DMA, HLA-DRA/B1, HLA-DQA1/B1, HLA-DPA1/B1).
In contrast, antigen presentation in Family X appeared more
similar to the normal pancreas, while PDAC was characterised by
up-regulation of HLA-B, HLA-DPA1, HLA-DQA1, HLA-DRB4,
TAP2, as well as genes involved in migration of antigen presenting
cells i.e. DMBT1 and CD29, which are not changed in familial
PanINs. Dendritic cell migration and macrophage recruitment
were also down-regulated in non-X families (decrease in CXCL12,
CXCR4, VCAM-1 and ICAM2 expression).
Humoral immune response was also significantly affected in
non-X families, with lower expression of RGS1 (B cell develop-
ment, activation and proliferation [17]) and complement system,
namely C3, C1QA/B/C, C4B, CFB and SERPING1
(Figure 4B). In contrast, EBF1, IL7R and PRDM1/BLIMP1
were up-regulated only in Family X, while up-regulation of
POU2AF1 and BCL6 (B cell growth, maturation and formation of
germinal centres) [18]) was seen in both PanIN-X and PDAC
samples. In PDAC only, C3, C1S, and CD55 were up-regulated,
and PDAC was characterised by a strong pro-inflammatory
response (up-regulation of TGFB1, TGFBR1, STAT2, STAT6,
SPP1, LIF). As BCL6 was recently shown to be one of the 12
stromal genes that can distinguish preinvasive from invasive
disease in esophageal carcinoma based on profiling of the
microdissected stroma only [19], we have selected this gene for
validation in pancreatic tissues. We show that the increased level of
BCL6 transcript (.2 fold) seen in PanIN-X and PDAC, is
contributed by strong nuclear immunoreactivity in the stromal
inflammatory cells (Figure 5A). Of 24 PanIN lesions on TMA1,
16 (67%) displayed inflammatory infiltrate, nine of which (56%)
(2/2 PanIN-1, 4/7 PanIN-2 and 3/7 PanIN-3) comprised BCL6
positive cells. Of 15 PDAC cases, 13 (87%) comprised inflamma-
tory infiltrate; 11 of these (85%), including four cancers with
PanINs, showed BCL6 immunoreactivity.
A prototypic damage-associated molecular pattern (DAMP) of
HMGB1/2 signalling was also evident, predominantly in PanIN-
Precursor Lesions in Familial Pancreatic Cancer
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X and PDAC (Figure 4B); this pathway signals through RAGE
[20]. To establish the localisation and expression of HMGB1, IHC
analysis was performed (Figure 5B). The nuclear immunoreac-
tivity was seen in both the exocrine and endocrine cells, as well as
in the immune stromal component. HMGB1 expression was seen
in 67% (16/24) of PanINs (3/4 PanIN-1, 5/10 PanIN-2 and 8/10
PanIN-3) from TMA1, in all PanINs found within 15 PDAC cases
and in 13/15 (87%) PDAC lesions (two PDAC cases with no/weak
Figure 1. The pedigrees of pancreatic cancer families analysed. (A–C) non-X families and (X) Family X.
doi:10.1371/journal.pone.0054830.g001
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expression were poorly differentiated). Of note, HMGB1 expres-
sion has already been associated with various cancer diseases (for
review see [21]). In PDAC, serum HMGB1 was recently reported
to correlate with stage, resectability and early vs late PDAC [22].
The DAMP superfamily includes also S100 genes, several of
which were up-regulated in PanIN-X: S100A4, S100A6, S100A7A,
S100A10, S100A13 and S100A16. Deregulation of S100A2 and
S100A11 was additionally seen in PDAC, while S100P was
commonly up-regulated in all PanIN lesions (X and non-X) and
PDACs, further substantiating the importance of S100 genes in the
development and progression of FPC as seen in sporadic cases
[23,24]. Further canonical pathways whose significance increased
with cancer progression were cytoskeleton and motility/invasion
(‘Actin cytoskeleton signaling’, ‘Regulation of actin-based motility
by Rho’ and ‘Ephrin signaling’) (Table S1); adhesion (‘Integrin
signaling’, ‘ILK signaling’ and ‘FAK signaling’) (Table S2); and
stromal response, with higher expression and number of ECM
genes seen as PanINs progress to PDAC (Figure 4B). A large
number of these clustered within ‘Hepatic fibrosis and stellate cell
activation’ (Table S3) and can potentially represent activation of
pancreatic stellate cells, which have been reported to have highly
similar profiles to hepatic stellate cells [25]. Furthermore, in
addition to COL1A1, COL1A2 and COL3A1, other collagens
(COL4-6A2 and COL12A1), and ECM genes (BGN, VCAN,
DCN, SPARC, SPON1 and THBS1) were up-regulated in PanIN-
X lesions and PDACs; in PDACs, stromal involvement was
characterised by an even higher diversity of collagens (COL10A1,
COL11A1, COL14-16A1 and COL18A1 were additionally seen),
and even higher expression than in PanIN-X lesions of the ECM
genes mentioned above. Importantly, COL11A1 was recently
Figure 2. Histology of PanIN lesions. The top panel shows the histology of three members of non-X-families (A1, B1 and C2). Images at the top
show PanIN-1 and -2 lesions (magnification6100); and images at the bottom show PanIN-3 lesions from family B and C; magnification6200). The
lower panel shows the histology of three different members of Family X: X1, X5 and X6 at the top show their gross appearance (magnification620);
images at the bottom show PanIN-1 from X1 sample (magnification6100); and PanIN-3 lesions from X5 and X6 (magnification6200). * indicates
adjacent histologically normal appearing tissue.
doi:10.1371/journal.pone.0054830.g002
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Figure 3. Hierarchical clustering of all the PanIN and PDAC lesions. (A) Venn diagram displays the numbers of common and unique probes
in PDAC progression; (B) Heatmap of 93 commonly dysregulated probes (76 genes) is shown on the right. Each column represents a type of
comparison and each row represents a gene probe. The level of up- and down-regulation is represented by the intensity of the red and green colour,
respectively.
doi:10.1371/journal.pone.0054830.g003
Figure 4. Functional modules and canonical pathways. (A) The significant functional modules commonly altered during the transition from
normal pancreas to PanIN and PDAC are shown. (B) Differences in most significantly affected canonical pathways between PanINs and PDAC samples
are presented. The horizontal lines parallel to the x-axis in both images indicate a P= 0.05 threshold.
doi:10.1371/journal.pone.0054830.g004
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Figure 5. Localisation and expression of BCL6 and HMGB1. (A) Representative images of BCL6 positive cells (brown staining) in the stroma in
the vicinity of PanIN lesions are shown in the top two panels (both magnified6100); two bottom images show inflammatory infiltrate with BCL6
immunoreactive cells in two PDAC cases (magnification6100 and650, respectively). (B) HMGB1 nuclear expression (brown staining) was seen in all
pancreatic compartments, including stromal immune infiltrate: top panels show PanIN-1 (left) and -2 (right) (magnification650, insert and second
panel x100); bottom panels show PanIN-3 (left) and PDAC (right) (magnification6100 and650, respectively).
doi:10.1371/journal.pone.0054830.g005
Precursor Lesions in Familial Pancreatic Cancer
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shown to be a specific marker of pancreatic stellate cells [26],
indicating that their accumulation is particularly pronounced in
PDAC. Significant accumulation of matrix metallo-proteinase and
cysteine proteinases was seen already in PanIN-X lesions,, with
increased levels of MMP1, MMP2 andMMP19, and CTSC, CTSE
and CTSK, respectively. Additional proteases (MMP7, MMP9,
MMP11, MMP14, MMP28 and CTSA and CTSB) were dereg-
ulated only in PDAC specimens.
Family X samples differed from both non-X PanINs and
PDACs in the deregulation of a number of genes involved in
insulin signalling and diabetes (INSR, IRS1 and 2, IGF1,
IGFBP2-BP7, CASR, ADIPOQ and NR5A2); this is illustrated
in Figure S2 and S3, with accompanying discussion).
Comparison of familial PanINs to data from sporadic
PDACs
Multiple comparisons of our data with previously published
reports were achieved using Pancreatic Expression database
(http://www.pancreasexpression.org/). When data from non-X
and X PanINs were compared to published profiles from
microdissected PanINs from sporadic PDACs [5,27], 44 and 185
deregulated genes were shared, respectively (Table S4). Three of
the commonly deregulated genes were successfully validated by
QRT-PCR: AGR2, S100P and EGR1. In addition, higher
expression of FOS in Family X PanINs and majority of PDACs
was also confirmed (Figure 6).
When non-X and X PanIN data were compared to dissected
and bulk sporadic PDAC profiles (references are listed in
Pancreatic Expression database), around 5% and 25% of overlap
was seen, respectively. This is less than was seen in our PanIN vs
PDAC comparison, and it is largely attributed to different
platforms and experimental techniques used.
Lastly, non-X and X PanIN transcriptomes were compared to
our PanIN-3 proteome [12], 46/900 (5%) and 132/900 (15%)
proteins matched the RNA transcripts, respectively; these data
independently validate our findings at the protein level
(Table S5A and B).
Common PanIN-PDAC progression gene signature
The heatmap in Figure 3B and Table S6 display the 93
probes representing 76 commonly differentially expressed tran-
scripts across all comparisons (X vs Normal, non-X vs Normal,
PDAC vs Normal).
More than 10 different enzymes were commonly down-
regulated, including the ones involved in synthesis and catabolism
of amino acids (ASNS, BCAT1, EPRS, SARS, YARS, PSAT1);
moreover, deregulation of several solute carriers points to an
impaired amino acid transport (SLC1A2, SLC1A4, SLC25A22).
Expression changes in SLC20A1, a sodium-dependent phosphate
symporter, and KCTD14 (potassium channel tetramerisation
domain-containing-14) suggests impaired ion transport as well.
Commonly expressed stromal genes include COL1A1, THBS1,
FMOD and SERPINE1 across all PanIN lesions and PDAC.
COL1A1, a major component of pancreatic desmoplasia pro-
motes invasion and metastasis in PDAC [28]. Increased expression
of THBS1 is a prognostic predictor of increased invasiveness in
PDAC [29] and correlates with the progression of metaplasia-
dysplasia and cancer in oesophagus [19]. In addition, THBS1 also
increases the expression of SERPINE1 [30], which is modestly up-
regulated in both non-X and X PanINs and strongly up-regulated
in PDAC. Therefore, while these stromal genes have previously
been associated with PDAC, we show that they are already over-
expressed in PanIN lesions prior to cancer formation.
One of the key regulators of the NFkB pathway, NFKBIZ, is
seen deregulated in all PanINs. Its up-regulation may contribute to
increased inflammation in the pancreas that favours tumour
progression [31]. Expression of an interleukin receptor, IL22RA1,
was decreased in PanINs and PDACs, but as this gene is mainly
expressed in the islet cells [32], islet cell loss could potentially
explain such result. CXCL12 was also commonly affected; it plays
a role in cancer spread/metastases via interaction with its receptor
CXCR4. Both CXCL12 and CXCR4 were down-regulated in
non-X PanINs, while only CXCL12 is down-regulated in the
PanIN X lesions, and the CXCR4 levels are normal. In contrast,
PDACs showed increased levels of CXCR4; this is a well-
established feature of many cancer types [33] and is a predictor of
poor survival in PDAC [34].
Several transcriptional factors were also found up-regulated in
both PanINs and PDACs: KLF3, KLF6 and EGR1.
Finally, REG3G and REGL, markers for pancreatic injury [35]
were consistently under-expressed in both PanINs and PDACs,
and indicate loss of acinar cells during PDAC development.
In silico comparison of our 76 commonly differentially expressed
PanIN/PDAC transcripts with our sporadic and familial PanIN-3
proteomics data ([12], and unpublished data) highlighted the
expression of nine of the 76 genes also at the protein level:
ACTA2, AGR2, AHCY, COL1A1, COPB2, HSPA5, HSPA8,
S100P and TFF1, providing thus an independent validation of our
profiling data. While we have previously shown that AGR2 is
expressed in both sporadic and familial PanINs [36], we here
additionally validated TFF1 by IHC using sections derived from
Family X tissues (Figure 7). This demonstrated the almost
universal expression of TFF1 in the familial precursor lesions (5/
10 PanIN-1, 9/9 PanIN-2 and 4/4 PanIN-3) as shown previously
in sporadic cases [37].
Discussion
While early description of PDAC precursor lesions dates back to
the 1950’s [38], and the hypothesis that atypical hyperplasia and
carcinoma in situ are precursors for PDACs is more than 30 years
old [39], the consensus PanIN nomenclature was established
relatively recently [3].
Despite several detailed histological and clinical studies [40],
and a report of increased prevalence of PanIN lesions in both
sporadic [41] and familial PDAC patients [42], our knowledge of
the underlying molecular events in these precursor lesions is still
limited. This is largely due to the inaccessibility of PanIN
specimens.
Here, we have analysed PanIN-2/3 lesions from pancreatecto-
my specimens derived from FPC without the presence of invasive
carcinoma, which is critical as it is often difficult to distinguish
between true PanIN-3 lesions and cancerisation of ducts by well-
differentiated invasive cancer in the specimen that contains both.
Only two similar small-scale studies have been reported on PanIN
lesions detected in the absence of cancer: Zhang et al [43] analysed
KRAS mutations and protein expression of p53, p16 and cyclin
D1 in PanINs in tumour-free heterotopic pancreas of PDAC
patients and Baumgart et al [44] analysed PanIN samples from a
patient with chronic pancreatitis that had PanIN-3 lesions; both
studies provide direct evidence for the PanIN-PDAC progression
model. The comprehensive molecular analyses presented here not
only provides definitive support of the progression model, but also
enabled us to investigate the underlying molecular pathways and
to assess the similarities between the sporadic and familial
precursor lesions on a genome-wide scale.
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While the similar prevalence of ‘signature’ mutations in sporadic
and familial PDAC specimens has previously been reported [45],
and mutation analyses in Family X conformed to these data [6],
we now show that on the transcriptome level, PanIN lesions in our
familial cases have also undergone similar changes as those seen in
sporadic cancer. Based on comparison of data from SEER
(Surveillance Epidemiology and End Results) database and data
on familial PanINs from Brune et al [46] Schwartz and Henson
[47] suggested that familial PDACs may have similar or
overlapping pathways to those of sporadic cases. We now provide
molecular evidence that this is indeed the case.
Two transcriptome studies of sporadic PanINs in the setting of
pancreatic cancer have been reported; Prasad et al [27] compared
microdissected PanIN-1B/2 lesions with normal ducts; Buchholz
et al [5] used microdissected material to compare PanINs of all
grades to normal ducts and PDACs, showing a steady increase in
number of differential transcripts with advanced dysplasia. These
studies used custom-made cDNA and oligo-based arrays, respec-
tively, with amplified fluorolabelled material from sporadic
PDACs; we used much larger coverage Affymetrix arrays with
the unamplified material from enriched primary PanIN-2/3
lesions that occurred in the absence of cancer. The overlap
between the genes across the three studies was around 4% for non-
X PanINs and 18% for Family X PanINs. Considering the limited
congruence reported between profiling studies [48] and the
differences between the three data sets, this is in fact a fair
amount of overlap. The discovery of common genes through such
disparate studies proves that these are robust genes uniformly
deregulated during PanIN progression.
Based on the volume of transcriptional changes in PanINs
derived from Family X and non-X families, with around 40% of
shared differential transcripts with PDAC, the PanIN lesions in
Family X appeared more molecularly attuned to cancer. These
transcriptional changes mirror both the histopathological and the
clinically more aggressive picture, as PDAC in Family X develops
,20 years earlier (median 40 years of age) and cancer in non-X
families 5–10 years earlier (median 54 years) than in sporadic
cancer.
The most pronounced differences between the PanIN lesions
from Family X and non-X families were seen in the immune
response: while the inflammatory response in non-X families was
generally deficient, with significant underrepresentation of genes in
the antigen presentation and humoral response pathways, the
immune response profile in Family X was in many aspects similar
Figure 6. Confirmation of gene expression profiling. QRT-PCR analysis validated the differential expression for AGR2, S100P, FOS and EGR1 in
primary PanIN lesions: PanA1, B1-3 and C1,2 represent non-X families, while PanX1 and 3 belong to Family X samples; PDAC1-7 represent seven
different PDAC specimens.
doi:10.1371/journal.pone.0054830.g006
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to PDAC. Interestingly, up-regulation of KIT, its ligand KITLG/
SCF and tryptase TPSAB1 were seen already in Family X PanINs.
KIT is a proto-oncogene associated with several tumours that
enhances proliferation and invasion of pancreatic cancer cell lines
[49]; KITLG/SCF and TPSAB1 are mast cell markers indicating
an early infiltration of stroma surrounding PanINs with mast cells.
A pro-inflammatory milieu composed of macrophages and mast
cells has been shown to promote cancer growth and invasion
[50,51]; mast cell inhibition has been proposed as a therapeutic
strategy for PDAC [52].
A further noticeable difference seen between the PanINs reflects
the Family X histology, which shows an extensive desmoplastic
change; this was characterised with both higher expression and
increased numbers of stroma-associated genes, indicating that the
stroma co-evolves with epithelial elements in the PDAC precursor
lesions. Similar findings have been reported in breast precursor
lesions, where extensive gene expression changes in the stroma are
associated with ductal carcinoma in situ (DCIS) [53]. Further
significant increases in expression of stromal genes were seen in
our PDAC data; the importance of the stroma in biology of
sporadic pancreatic cancer is well recognised [54,55]. All together,
these data indicate that co-operating transcriptional changes in
both tumour and its microenvironment can dramatically alter the
natural history of the disease and that monitoring both compart-
ments might also provide a better predictor of pancreatic cancer
evolution in the familial setting.
Seventy-six common genes were uniformly affected throughout
the disease evolution and appear to be fundamental to neoplastic
progression in pancreatic cancer regardless of whether it is
sporadic or familial. Within this gene set, we highlight two genes,
S100P and AGR2, which with COL1A1 show the highest over-
expression in both PanIN and PDAC lesions in the current
analysis as well as in our previously published data. Both have
already been involved in development and progression of sporadic
PDAC: S100P expression increases with the PanIN grade [24],
and AGR2 is uniformly expressed from earliest PanIN-1 lesions
[36,56]. As these two proteins are expressed also in familial lesions
they represent promising diagnostic, preventive and therapeutic
targets.
The 76 common genes observed are markers of dysplastic
lesions that underlie neoplastic progression, we thus propose that
this core neoplastic profile might be useful in monitoring of PanIN
progression and could form a basis for the design of a molecular
test to be used in conjunction with EUS/MRCP surveillance.
While the number of affected members in the kindred increases
the risk of PDAC development, given the varying risks for PDAC
between kindreds with heterogenous clinical syndromes, it is
challenging to differentiate the patients who will develop rapid
neoplastic progression from the ones with the stable disease and to
identify which groups will benefit most from a comprehensive
pancreatic cancer surveillance program. Currently, if abnormal
EUS and MRCP findings warrant a tissue diagnosis, a partial
pancreatectomy with detailed histopathological examination is
performed. Inclusion of an additional, sensitive molecular assay,
could be instrumental in the decision on how to proceed (further
surveillance versus pancreatectomy). Moreover, this transcriptome
profile could be used in conjunction with needle biopsies of
indeterminate lesions of the pancreas in high-risk settings to
identify progressing PanIN-3 lesions.
Figure 7. Expression of TFF1 in familial PanIN lesions. Panel (A) shows PanIN-1 with no TFF1 immunoreactivity, (B) and (C) PanIN-2 and (D)
PanIN-3 lesion in the centre with strong TFF1 expression (all magnified x100).
doi:10.1371/journal.pone.0054830.g007
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Nine of the obtained 76 PanIN/PDAC common genes: were
independently validated by in silico comparison with our PanIN-3
proteomics data: ACTA2, AGR2, AHCY, COL1A1, COPB2,
HSPA5, HSPA8, S100P and TFF1. Protein validation of
abnormally expressed transcripts was also performed by IHC
(AGR2, TFF1) and CYR61, detected in our transcriptome studies,
was recently reported to be expressed in (sporadic) PanIN and
PDAC samples [57]. It will now be critical to further confirm the
validity of our proposed panel in an independent set of familial/
sporadic cases ideally through multi-center retrospective studies.
In that respect, it is of great importance that another three genes
seen in our transcriptome PanIN data are shown to be a part of a
six gene signature recently reported to predict survival of PDAC
patients [58]: FOSB was over-expressed in Family X PanINs and
was just below the significance cut off in non-X families, and
NFKBIZ and KLF6 are within our common 76 gene set.
The major limitation of the present study is a relatively small
number of samples analysed as well as the paucity of the obtained
material; the infrequent availability of primary PanIN lesions in
the absence of pancreatic cancer, limits a more extensive
validation of the results. Also, for gene expression profiling, we
used enriched (macrodissected), rather than microdissected sam-
ples in order to both avoid amplification of the material and to be
able to assess the stromal and immune response to PanIN growth
(as these are increasingly highlighted as critical to cancer
progression [19]), although we were aware that this would
preclude the assignment of expression changes to individual stage
of PanINs. Both of these limitations were, however, circumvented
by extensive analyses and comparisons to both dissected and bulk
pancreatic specimens using the most recently updated version of
Pancreas Expression database [59] which allowed us to integrate
our results and present them in the context of previously reported
data, as well as to perform large-scale in silico validation of our
results. Of note, all the data sets obtained in our study will (upon
publication) be included into our database and made available for
further mining to wider pancreas cancer research community.
In summary, our comprehensive analysis of unique clinical
specimens provides sufficient evidence to support the concept that
the PanIN-2/3 lesions are true non-invasive precursors of PDACs,
that familial precursor lesions share the fundamental signalling
pathways seen in sporadic pancreatic cancers, and that it is the
accumulation and the volume of concomitant changes at the
transcriptome level in both in the epithelial and stromal compart-
ments, as well as the pro-inflammatory milieu that dictate the speed
of progression of PanINs to PDAC also in the familial setting.
Materials and Methods
Ethics Statement
All specimens used in this study were collected with patient
consent and under protocols approved by the Institutional Review
Board at the University of Washington (Seattle, Washington,
United States).
Sample preparation and RNA isolation
13 PanIN specimens from pancreatectomies were analysed: six
originated from non-X (one from Family A, three from Family B
and two from Family C) kindreds and seven were from four
different patients from Family X. Further four specimens from two
donor pancreata and six sporadic PDACs were also used. Of note,
sporadic PDAC samples were used due to unavailability of the
matched cancer samples from the analysed families, as profiled
lesions were obtained before cancer has developed (in cases where
members of the family did present with cancer, it was already in an
advanced stage, so patients were not amenable to surgery and the
samples could not be procured).
In order to preserve the stromal response which is critical for
growth of PDAC, we have not microdissected the specimens;
however, following detailed histopathological analyisis, frozen
tissue blocks that comprised most pronounced multifocal PanIN-
2 with focal PanIN-3 lesions were selected for RNA isolation.
While PanIN lesions from non-X family samples were often
surrounded by histologically normal-appearing acinar cells with
PanIN lesion cellularity around 30–40%, Family X samples were
characterised by much more widespread precursor lesions, with
cellularity around 60%. The estimated percentage of high grade
PanINs in the specimens was around 10–15%. PDAC specimens
were classified as T2N1M0 and comprised .60% of cancer cells.
Total RNA was isolated using TRIzol reagent (Invitrogen Life
Technologies) according to the manufacturer’s protocol. The
quantity and quality of the samples were assessed using Thermo
Scientific NanoDrop 1000 spectrophotometer and Agilant 2100
Bioanalyzer, respectively.
Expression profiling and data analysis
Expression profiling was performed using GeneChip HG-
U133 set of arrays (Affymetrix, Santa Clara, CA, USA). Ten
micrograms of total RNA was reverse transcribed, biotin-
labelled, fragmented and hybridized to arrays, all according to
the manufacturer’s instructions (Affymetrix, Santa Clara, CA,
USA). The arrays were scanned with a GeneChip scanner 3000
7G. After scanning, raw. CEL files were analyzed using
Bioconductor (http://www.bioconductor.org/) packages within
the open source R statistical environment (www.r-project.org).
After quality control inspection, data were normalised jointly
using the Robust Multi-array Average (RMA) algorithm and
filtered using standard deviation calls to select the most
deregulated probes across all experiments. To account for
technical replicates, the ‘‘duplicateCorrelation’’ function was
used [60]. Genes differentially regulated between the biological
groups were identified using limma [61]. The Benjamini and
Hochberg (BH) false discovery rate was used for multiple testing
corrections; a double cut-off of false discovery rate (FDR) ,0.05
and unlogged fold change of $2 was used.
Quantitative Real-Time PCR (QRT-PCR)
Deregulation of AGR2, S100P, EGR1 and FOS was validated
using TaqMan probes AGR2/Hs00180702_m1; S100P/
Hs00195584_m1; EGR1/ Hs00152928_m1 and FOS/
Hs00170630_m1 from Applied Biosystems (Foster City, CA,
USA). One mg of total RNA was reverse transcribed and
triplicated PCR reactions carried out on ABI 7500 system. 18S
was used as endogenous control. Data were analyzed using SDS
version 1.3 (Applied Biosystems).
Pathway analysis
Ingenuity Pathway analysis (IPA) is a web-based application
(www.Ingenuity.com) that enables building of functional modules
and biological networks based on entered data and published
associations that are compiled, manually curated, and stored in the
IPA knowledge database, IPKB. Differentially expressed genes
were interrogated and scores for each generated network reported,
thus ensuring that contributing genes are not selected by random
chance (for example, a score of 2 gives 99% confidence, with
higher scores signifying greater confidence). Thus, IPA prioritizes
the networks, identifies the associated genes, and assigns the most
significant biological functions and corresponding canonical
pathways to each network. The global functional analysis
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calculates this significance using the right-tailed Fisher’s exact test,
with a P value ,0.05 being significant.
Immunohistochemistry
Validation of BCL6 and HMGB1 was performed on tissue
microarray (TMA1) comprising 32 cores representing 21 different
cases comprising 24 sporadic PanIN lesions (four PanIN-1, ten
PanIN-2 and ten PanIN-3), as well as on 15 sporadic PDAC cases
(within these, seven PanIN-1, four PanIN-2 and five PanIN-3 were
found). In addition, validation of TFF1 was performed on TMA2
comprising 60 cores representing 11 different FFPE tissue blocks
from Family X members (ten PanIN-1, nine PanIN-2 and four
PanIN-3). Immunohistochemical staining was performed on 4 mm
paraffin-embedded tissue sections using the Ventana Discover-
yTM System, Illkirch, France (www.ventanadiscovery.com) fol-
lowing the manufacturer’s protocols. Following antibodies were
used: rabbit polyclonal anti-BCL6 antibody (HPA004899) from
Sigma-Aldrich (1:30 dilution), rabbit polyclonal anti-HMGB1
antibody (ab18256) from Abcam (1:1000 dilution), and rabbit
polyclonal anti-estrogen inducible protein pS2 (TFF1) antibody
(ab50806) from Abcam (1:100).
Supporting Information
Figure S1 The dendrogram shows relationships within
20 pancreas tissue samples (two normal donor pancre-
ata with one replicated sample, 13 PanINs and four
PDACs) based on top 12,000 most variable genes. Normal
pancreas is denoted N, PanINs in Family X and PanINs in non-X
families are denoted as PanX and PanA-C, respectively, and
pancreatic cancer is denoted as PDAC. Of note, two PDAC and a
replicate of one normal specimen were removed during the
hybridisation quality assessment.
(TIF)
Figure S2 Affected genes within Diabetes mellitus
signaling pathway.
(TIF)
Figure S3 Accompanying data for Figure S2.
(DOC)
Table S1 Deregulated genes involved in actin cytoskel-
eton and motility.
(XLS)
Table S2 Deregulated genes involved in integrin signal-
ing and adhesion.
(XLS)
Table S3 Fibrosis and stellate cell response.
(XLS)
Table S4 Comparison with published sporadic PanIN
gene expression profiles.
(XLS)
Table S5 Comparison of non-X (A) and PanIN-X
samples (B) to PanIN proteomics data.
(XLS)
Table S6 93 probes representing 76 commonly ex-
pressed genes in all PanIN and PDAC samples.
(XLS)
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